Kura Oncology

Kura Oncology (operating at kuraoncology.com) is a clinical-stage biopharmaceutical company pioneering precision oncology. Founded in 2014 and headquartered in San Diego, California, Kura Oncology specializes in discovering and developing novel cancer therapeutics designed to improve patient outcomes through targeted, innovative treatments. Unlike traditional one-size-fits-all cancer therapies, Kura Oncology’s approach leverages advanced biotechnology to identify and develop medicines tailored to specific genetic mutations and molecular pathways driving tumors. This precision-driven methodology enables clinicians to deliver more effective, less toxic treatments, extending survival rates and enhancing quality of life for patients. The company’s pipeline includes multiple clinical trials exploring next-generation oncology solutions, supported by a robust research infrastructure. Backed by $150 million in funding, Kura Oncology is positioned to accelerate its mission of bringing transformative precision medicines to those in need.